Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Hopec Pharma
Hopec Pharma Overview
Hopec Pharma leads in innovative cancer treatments, focusing on Non-Muscle Invasive Bladder Cancer (NMIBC). Our product, Hopec, employs genetically modified Uropathogenic E. coli for targeted immune responses against cancer cells. This method offers higher efficacy and fewer side effects than traditional Bacillus Calmette-Guérin (BCG) therapy and addresses global BCG shortages with a scalable alternative. Our preclinical results have been outstanding, demonstrating significant potential for clinical success.
Founded by seasoned pharmaceutical professionals Gadi Klarsfeld and Estee Rosen, Hopec Pharma combines over 60 years of healthcare management and business expertise. Our scientific team includes Prof. Ofer Mandelboim, a leader in immunotherapy, and Prof. Gilad Bachrach, an expert in bacterio-oncology, both from Hebrew University. Prof. Chamutal Gur from the Weizmann Institute is an expert in natural killer (NK) cells, and Dr. Vladimir Yutkin, Director of Urologic Oncology at Hadassah Hospital, further strengthens our expertise.
Our innovative approach uses a safe, modified bacterium that effectively targets and destroys cancer cells, surpassing existing BCG treatments in efficacy and safety in preclinical trials. We're initiating a compassionate program at Hadassah and Sheba hospitals to demonstrate early human results. Hopec Pharma holds strong intellectual property positions with key patents in the U.S., Europe, and other markets, ensuring a competitive edge.
The market for our NMIBC treatment is vast, projected to reach $8.6 Billion by 2032. We are strategically positioned to capture this market, starting with high-grade patients, and planning to expand as we validate our treatment's effectiveness.